Supplementary Appendix

**Appendix 1.** Proposed phenotype categorization and treatment recommendations

| Phenotype   | Recommended Therapy                                         |
|-------------|-------------------------------------------------------------|
| Asymptomatic| No therapy                                                  |
| Acute       | Corticosteroid therapy                                     |
| Chronic     | Non-biologic therapies (antimetabolites) and other second line therapies |
| Advanced    | Third line therapy (biologics)                             |
Appendix 2. Delphi consensus regarding factors that should be important in decisions on whether to treat pulmonary sarcoidosis at presentation.

| Factor                        | Mean  | Std Dev |
|-------------------------------|-------|---------|
| Patient preference            | 2.59  | 2.38    |
| Symptom severity and QOL impact | 4.18  | 0.91    |
| Imaging studies               | 2.55  | 2.34    |
| Pulmonary function tests      | 3.68  | 1.17    |
| Extrapulmonary disease        | 4.00  | 0.93    |
| Pulmonary hypertension        | 3.55  | 2.09    |
| Need for oxygen               | 2.86  | 1.93    |
| Progressive disease           | 4.68  | 0.57    |
| Stability of disease          | 2.64  | 2.57    |
| Cardiac MRI                   | 3.09  | 1.41    |
| Ophthalmologic examination    | 3.41  | 2.15    |

Mean Delphi Score
Appendix 3. Step line therapy based on clinical phenotype in sarcoidosis.